Weill Cornell Medicine has been awarded a five-year, $5 million grant from the National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to establish a new multi-institutional center for tuberculosis (TB) research and training the next generation of TB investigators.
A better understanding of the biology of tuberculosis (TB) infection and improved drug combinations for the disease are two areas of research in which the TB Drug Accelerator (TBDA) has made strides since its inception a decade ago.
A team of scientists from Weill Cornell Medicine and Texas A&M University has identified a tuberculosis (TB) protein that future drugs might be able to target, with minimal side-effects compared to current treatments—potentially a critical discovery given the global public health crisis of drug-resistant TB.
Winner of a prestigious fellowship for postdocs, Dr. Adrian Jinich aims to spur health in developing countries—and inspire the next generation of STEM students.
A leading drug for tuberculosis (TB) that has begun to lose its potency due to antibiotic resistance can be used to combat the infection through more than one pathway.
Dr. Adrian Jinich, a postdoctoral associate in medicine in the Division of Infectious Diseases at Weill Cornell Medicine, has been selected as a 2019 Hanna H. Gray Fellow by the Howard Hughes Medical Institute (HHMI).
Dr. Kyu Rhee, an associate professor of medicine in the Division of Infectious Diseases at Weill Cornell Medicine, has been awarded a Physician-Scientist Institutional Award by the Burroughs Wellcome Fund.
Physicians, researchers and policymakers around the globe are grappling with the rise of antibiotic-resistant bacteria—a threat with the potential to derail decades of medical advances.
